September 12, 2016 – Proton Partners International Ltd has been awarded the prestigious International Organisation for Standardisation (ISO) 9001:2008 certificate for Quality Management Systems.

ISO 9001:2008 is the internationally recognised standard for quality management systems (QMS), which enables organisations to demonstrate that they have leadership, resources and processes in place to consistently deliver quality products and services whilst also meeting statutory and regulatory requirements.

Proton Partners was awarded the certificate by AJA Registrars following a two stage audit which involved the sampling of selected evidence in the form of documents, policies, procedures and records, supported by interviews with personnel, and observation of working practices. Leadership, commitment to quality and customer focus also formed part of the audit against this international standard.

Following the successful review, Proton Partners was awarded the ISO 9001:2008 certificate for ‘Management of a range of cancer treatment service facilities in the UK and overseas, which provide diagnostics, chemotherapy, radiotherapy, proton beam therapy, programme management and training.’

Mike Moran, Chief Executive of Proton Partners International, said: "Achieving ISO 9001:2008 accreditation so early in the Company’s life is a cornerstone to the Company’s future success. This is the first of many such accreditations that the Company will seek to achieve, all of which will support our drive for sustainable excellence.

“We have developed four Pillars of Excellence, the two central Pillars; The Patient Experience and Improving Cancer Care, puts the patient at the centre of the Company’s activities, while the other two Pillars; Operational and Clinical Excellence and Advancing Proton Beam Therapy, support activities for sustainability.

“I am extremely proud to lead a team that puts such emphasis on quality and excellence. The staff have worked tirelessly to gain ISO 9001:2008 accreditation and to drive home the desire to achieve excellence right across the Company.”

International Standards are strategic tools and guidelines to help companies tackle some of the most demanding challenges of modern business. They ensure that business operations are as efficient as possible, increase productivity and help companies access new markets.

Benefits of the ISO 9001:2008 standard include:

• Enhanced customer satisfaction and improved customer loyalty leading to repeat business;
• Increased revenue and market share obtained through flexible and fast responses to market opportunities;
• Integration and alignment of internal processes which will lead to increased productivity and results;
• Enhanced business performance and better cost management;
• Providing confidence to interested parties as to the consistency, effectiveness and efficiency of the organisation;
• Increased credibility and competitiveness in the market;
• Consistency in the delivery of clinical services;
• Lower costs and shorter cycle times through effective use of resources;
• Improved communication, planning and administration processes.

Proton Partners receipt of the prestigious certificate follows closely behind the news that work has now commenced on Proton Partners’ Northumberland site. The centre, situated at the Earth Balance wellness site in Bomarsund will be the second to be built by Proton Partners International in the UK and is expected to be operational by February 2018.

About Proton Partners International Limited
Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, which partners the Italian Hadron Centre in Pavia, has been appointed non-executive chairman and Professor Karol Sikora is chief medical adviser to the company.

The Welsh Government’s Life Sciences Investment Fund is a key investor in Proton Partners International.

About Proton Beam Therapy
Proton beam therapy is a highly-targeted type of radiotherapy that can treat hard-to-reach cancers, such as spinal tumours (chordomas), with a lower risk of damaging the surrounding tissue and causing side effects.